Interrelationship of anti-oxidative status and circulating biochemical markers in patients with cancer experience tumor lysis syndrome (TLS)

Paper Details

Research Paper 01/04/2020
Views (282) Download (14)

Interrelationship of anti-oxidative status and circulating biochemical markers in patients with cancer experience tumor lysis syndrome (TLS)

Maria Amjad, Arif Malik, Khadija Mastoor, Sana Noreen, Bahisht Rizwan
Int. J. Micro. Myco.11( 4), 1-7, April 2020.
Certificate: IJMM 2020 [Generate Certificate]


Tumor lysis syndrome is metabolic abnormality arises in response to anti-cancer treatment. It may develop in both pediatric or adult cancer and thought to be high risk oncologic emergency. Chemotherapy is one of the frequent method for the treatment of cancer patients. Fifty patients of TLS and Twenty age and sex-matched clinically apparently healthy individuals were eligible for inclusion in the study. 5 ml blood sample were taken and subjected to centrifuge at 4000-5000rpm for 10-15 minutes for the separation of serum. The level of MDA, SOD, CAT, GSH, VIT A, VIT C, VIT E, Nitric oxide (NO), Neuraminidase, Electrolytes (Na+, K+) TNF-alpha and IL-2 were estimated. The MDA level in TLS patients was increased (6.35±2.16) as compared to control (2.57±0.81) and statistically significant (0.026<0.05). SOD level decreased in TLS patients (0.954±0.065) as compared to healthy individuals (1.38±0.16) and statistically significant (0.003<0.05). TNF-alpha level in TLS patients was elevated (36.35±4.26) as compared to control (24.98±3.78) and statistically significant (0.032<0.05). IL-2 level was also raised in TLS patients (331.55±0.24) as compared to healthy ones (263.17±1.97). Nitric oxide and Neuraminidase level in TLS patients was higher (41.26±2.54 and 8.06±2.26 respectively) as compared to control group (17.78±2.67 and 7.26±2.16 respectively). Present study showed the relationship present between Oxidative stress, Vitamins, Electrolytes, IL-2, TNF-alpha and TLS. These results confirm a perfect sketch regarding circulating biomarkers and lipid peroxidation. Increased level of MDA as a biomarker of lipid peroxidation, IL-2 and TNF-alpha is the cause for the progression of the disease.


Ahamed SM, Varma RS, Mathew T, Hamide A & Badhe BA. 2006. Spontaneous tumour lysis syndrome associated with non-Hodgkin’s lymphoma. A case report. The Indian Journal of Pathology and Microbiology 49, 26-28.

Altman A. 2001. Acute tumor lysis syndrome. Seminar in Oncology 28, 3-8.

Anderson S, Files J. 2002. Tumor lysis syndrome secondary to Gemtuzumab Ozogamicin in a patient with acute myelogenous leukemia. Mississippi State Medical Association 43, 105-6.

Arrambide K, Toto RD. 1993. Tumor lysis syndrome. Seminar in Nephrology 13, 273-80.

Barquero BJ, Catalina F, Hernandez SC, Jimenez MJ, Garcia de-la LF. 2005. Spontaneous tumor lysis syndrome in a patient with non-Hodgkin’s lymphoma. Anmend International Medicine 22, 387-389.

Benekli M, Gullu IH, Savas MC. 1996. Acute tumor lysis syndrome following intrathecal methotrexate. Leukemia & Lymphoma 22, 361-3.

Benekli M, Savas MC, Gullu IH. 1995. Tumor lysis syndrome following single dosemitoxantrone. Chemotherapy 41, 470-2.

Cairo MS, Bishop M. 2004. Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology 127, 3-11.

Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. 2008. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of Clinical Oncology 26, 2767-78.

Crittenden DR, Ackerman GL. 1977. Hyperuricemic acute renal failure in disseminated carcinoma. Archives of Internal Medicine        137, 97-99.

Davidson MB, Thakkar S, Hix JK. 2004. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Amerixcan Journal of Medicine 116, 546-54.

Gago-Dominguez M, Castelo JE. 2006. Lipid peroxidation and renal cell carcinoma further supportive evidence and new mechanistic insights. Free Radical Biology and Medicine      40, 721-733.

Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou E, Harvey E, Cairo MS. 2001. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97, 2998-3003.

Hagemeister F, Huen A. 2005. The status of allopurinol in the management of tumor lysis syndrome: A cancer journal for clinicians 11, 1-10.

Hijiya N, Metzger ML, Pounds S. 2005. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocyticleukemia. Pediatric Blood Cancer 44, 63-9.

Hochberg J, Cairo MS. 2008. Tumor lysis syndrome: Current perspective. Haematologica 93(1), 9-13.

Howard SC, Pui CH. 2006. Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma 47, 782-5.

Hussain K, Mazza JJ, Clouse LH. 2003. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): Case report and review of the literature. American Journal of Hematology 72, 212-5.

Jasek AM, Day HJ. 1994. Acute spontaneous tumor lysis syndrome. American Journal of Hematology 47, 129-131.

Jeha S. 2001. Tumor lysis syndrome. Semnar in Hematology 38, 4-8.

Jones DP. 2000. Redox state of glutathione in human plasma. Free Radical Biology and Medicine 28, 625-635.

Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CL. 2007. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Southern Medical Journal 100, 916-917.

Locatelli F, Rossi F. 2005. Incidence and pathogenesis of tumor lysis syndrome. Contribution to Nephrology 147, 61-8.

Masella R. 2005. Novel mechanisms of natural antioxidant compounds in biological systems: Involvement of glutathione and glutathione related enzymes. Journal of Nutritional Biochemistry 16, 577-586.

Mates JM, Perez Gomez C, Nunez CL. 1999. Antioxidant enzymes and human disease. Clinical Biochemistry 32, 595-603.

Nakamura M, Oda S, Sadahiro T. 2009. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfusion and Apheresis Science 40, 41-7.

Opyrchal M, Figanbaum T, Ghosh A, Rajkumar V, Caples S. 2010. Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. Case Report in Medicine, 1-3.

Pentheroudakis G, O’Neill VJ, Vasey P, Kaye SB. 2001. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumors. Report of two cases. Support Care Cancer 9, 554-557.

Riccio B, Mato A, Olson EM, Berns JS, Luger S. 2006. Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biology and Therapy     5, 1614-1617.

Rostom AY, El-Hussainy, Kandil A, Allam A. 2000. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Annals of Oncology 11.

Seki JT, Al-Omar HM, Amato D, Sutton DM. 2003. Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Annals of Pharmacotherapy 37, 675-8.